Author

admin

Browsing

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) is trading at three-year highs in response to breakthrough innovations and increased deals for biotech stocks on the NASDAQ.

After dropping to a low of 3,637.05 in October 2023, the index climbed to a high of 4,954.813 on September 19, 2024. While the NBI is trading down at 4,399.36 as of January 7, 2025, further growth could be in store in the future. However, the current economic environment means the biotech sector may have a complex road ahead.

According to a recent report from Precedence Research, the global biotech market is expected to grow at a compound annual growth rate of 11.5 percent from now to 2034, reaching a valuation of US$4.61 trillion.

Driving that growth will be favorable government policies, investment in the sector, increased demand for synthetic biology and a rise in chronic disorders such as cancer, heart disease and hypertension.

The top NASDAQ biotech stocks have seen sizeable share price increases over the past year. For those interested in investing in biotech companies, the best-performing small-cap biotech stocks are outlined below.

Data was gathered on January 7, 2025, using TradingView’s stock screener, and all top small-cap biotech stocks in the list had market caps between US$50 million and US$500 million at that time.

1. Bright Minds Biosciences (NASDAQ:DRUG)

Company Profile

Year-over-year gain: 2,232.41 percent
Market cap: US$281.1 million
Share price: US$40.22

Bright Minds Biosciences is developing novel treatments for pain and neuropsychiatric disorders such as epilepsy, post-traumatic stress disorder and difficult-to-treat depression.

The company’s platform includes serotonin agonists designed to provide powerful therapeutic benefits while minimizing the side effects.

Bright Minds is currently in Phase 2 clinical trials for its BMB-101, a highly selective 5-HT2C receptor agonist, in adult patients with classic absence epilepsy and developmental epileptic encephalopathy.

Bright Minds Biosciences’ stock rocketed upwards in the fourth quarter, shooting up from US$2.49 to US$38.49 in one day on October 15. The company issued a press release stating it was ‘unaware of any material changes in the company’s operations’ that would have contributed to such a rally. The outperformance instead appears to be related to the October 14 announcement of Danish pharma company Lundbeck acquiring Longboard Pharma, another biotech company developing a 5-HT2C receptor agonist, for US$60 per share.

A few days later, Bright Minds announced a non-brokered private placement of US$35 million, which sent shares up to US$47.21 on October 18.

That same month the company shared its collaboration with Firefly Neuroscience (NASDAQ:AIFF) to use the latter’s advanced artificial intelligence, FDA-cleared BNA technology platform to provide a full analysis of the electroencephalogram (EEG) data from Bright Minds’ BMB-101 Phase 2 clinical trial. This follows the pair’s previous successful collaboration to analyze data from Bright Mind’s first-in-human Phase 1 study of BMB-101.

Bright Minds’ share price reached their highest yearly peak of US$55.77 on November 6.

2. Candel Therapeutics (NASDAQ:CADL)

Company Profile

Year-over-year gain: 518.52 percent
Market cap: US$371.37 million
Share price: US$8.35

Candel Therapeutics is a biotech company focused on developing oncology treatments. The company’s pipeline includes two clinical stage multimodal biological immunotherapy platforms.

Candel’s lead product candidate CAN-2409 is in a Phase 2 clinical trial in non-small cell lung cancer and borderline resectable pancreatic cancer, as well as Phase 2 and 3 trials for localized, non-metastatic prostate cancer. Positive interim data for the trial on pancreatic cancer, released on April 4, 2024, sent the company’s share price spiking upwards. It ultimately climbed to a year-over-year high of US$14.30 on May 16.

More recently, in December 2024, the company released positive topline data for CAN-2409 viral immunotherapy, achieving the primary endpoint in its Phase 3 prostate cancer trial.

Its second lead product candidate is CAN-3110, which is in an ongoing Phase 1 clinical trial in recurrent high-grade glioma (HGG).

The company had a number wins with the US Food and Drug Administration (FDA) in 2024. In February, Candel’s CAN-3110 received regulatory approval for a fast-track designation for the treatment of recurrent HGG. The agency also granted Candel orphan drug designation for CAN-2409 for the treatment of pancreatic cancer in April and CAN-3110 for HGG in May.

3. Rezolute Bio (NASDAQ:RZLT)

Company Profile

Year-over-year gain: 467.04 percent
Market cap: US$314.63 million
Share price: US$5.43

Late-stage biopharma company Rezolute is developing novel therapies targeting rare and chronic metabolic diseases. At the top of the company’s drug pipeline is RZ358, called ersodetug, which is being studied for the treatment of congenital hyperinsulinism and tumor hyperinsulinism. The company also has RZ402, which is targeted for patients with diabetic macular edema.

Ersodetug is currently in global Phase 3 clinical studies for congenital hyperinsulinism, with topline data expected in mid-2025. It opened to US participation in September after the FDA removed partial clinical holds.

In March, Rezolute shared results from a preclinical study that validated ersodetug’s potential to treat patients with non-islet cell tumors that have uncontrolled hypoglycemia. Rezolute announced positive topline results for its Phase 2 study of RZ402 in May.

The biotech stock had a great run up in the second quarter this year, climbing to an H1 2024 high of US$6.799 on June 5. Since then, Rezolute shares have managed to retain much of that value with a series of positive news releases.

The company closed on a public offering with net proceeds of about US$56.4 million later in June, which will help to fund post-Phase 3 planning for its ersodetug program in congenital hyperinsulinism as well as a potential late-stage, registrational, clinical study of ersodetug in patients with tumor hyperinsulinism associated with islet cell and non-islet cell tumors.

In August, the FDA granted clearance for Rezolute’s investigational new drug application for a Phase 3 study of ersodetug in tumor hyperinsulinism. Patient enrollment is slated to begin in the first half of 2025. In December, the FDA granted ersodetug orphan drug status for the treatment of hypoglycemia due to tumor HI.

Rezolute kicked off the new year with another FDA approval, this time garnering the breakthrough therapy designation for ersodetug for the treatment of hypoglycemia due to congenital hyperinsulinism.

4. Entera Bio (NASDAQ:ENTX)

Company Profile

Year-over-year gain: 301.52 percent
Market cap: US$97.61 million
Share price: US$2.65

Entera Bio’s proprietary N-Tab technology oral delivery platform allows for the development of therapies based on peptides and therapeutic proteins. The company is targeting a variety of indications, including osteoporosis, hyperparathyroidism and short bowel syndrome.

The company released a series of significant updates in March and April. This included the announcement of positive pharmacokinetic data for GLP-2 peptide tablet treatment for patients with short bowel syndrome as part of a joint study combining OPKO Health’s (NASDAQ:OPK) proprietary long acting GLP-2 agonist with Entera’s N-Tab technology.

In April, Entera announced the publication of Phase 2 clinical trial data from its EB613 program for osteoporosis. Unlike available osteoanabolic treatments, which are injections, EB613 is a once daily treatment administered through oral PTH(1-34) peptide tablets. According to the release, ‘Significant gains in bone mineral density of the spine and hip were observed at the end of the 6-month study and there were no significant safety concerns.’

Entera Bio’s share price reached its yearly peak of US$2.98 on April 12, 2024.

5. Benitec Biopharma (NASDAQ:BNTC)

Company Profile

Year-to-date gain: 251.42 percent
Market cap: US$258.63 million
Share price: US$11.14

California-based Benitec Biopharma is advancing novel genetic medicines via its proprietary “Silence and Replace” DNA-directed RNA interference platform. The company is currently focused on developing therapeutics for chronic and life-threatening conditions including oculopharyngeal muscular dystrophy (OPMD). Its drug candidate BB-301 was granted orphan drug designation by the FDA and the European Medicines Agency.

In April, Benitec reported positive interim clinical trial data for its first OPMD subject treated with BB-301 in its Phase 1b/2a study. Following the report, Benitec’s share price began trending upward, and reached US$10.47 on May 10.

Benitec is well-funded to advance its BB-301 clinical development program through the end of 2025. The company reported additional positive interim safety and efficacy data in mid-November. The company’s share price hit its highest yearly value on December 11 at US$13.08.

Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

The two best teams in the NBA — the Cleveland Cavaliers and Oklahoma City Thunder — squared off in the first game in league history featuring clubs on 15 and 10 games winning streaks.

Oklahoma City entered Wednesday’s showdown having won 15 games in a row, while Cleveland came into the contest winners of 10 straight.

In an exciting and tense back-and-forth game, the NBA’s best Cavaliers extended their winning streak to 11 games after defeating the Western Conference’s best Thunder 129-122 at Rocket Mortgage FieldHouse in Cleveland.

The marquee matchup had 30 lead changes.

Cleveland has won at least 11 straight games for the second time. The Cavs started the season 15-0.

Oklahoma City’s 15-game winning streak is snapped as the Thunder suffered its first loss since December 1

Seven Cavaliers finished in double-digits led by center Jarrett Allen who had 25 points, 12 rebounds, six assists and three steals. Power forward Evan Mobley added 21 points, 10 rebounds and seven assists.

“It felt like a battle the whole night. They were scoring. We were scoring, getting stops on both sides. At the end of the night, it came down to which team had more effort,” Allen said after the victory.

Allen and Mobley are the first Cavaliers’ teammates with at least 20 points, 10 rebounds and five assists since LeBron James and Dwyane Wade on November 17, 2017.

Thunder all-star guard Shai Gilgeous-Alexander had a game-high 31 points on 13-of-27 shooting and forward Jalen Williams finished with 25 points, nine assists and five rebounds in the losing effort.

The Cavs and Thunder will meet again on January 16 at the Paycom Center in Oklahoma City.

Cleveland improved to 32-4 and next hosts the Toronto Raptors on Thursday.

Oklahoma City dropped to 30-6 and take on the New York Knicks at Madison Square Garden in New York on Friday.

This post appeared first on cnn.com

President Joe Biden will no longer travel to Rome, Italy, this week as scheduled, the White House announced late Wednesday, canceling the trip in the final days of his presidency to monitor raging wildfires across the Los Angeles, California, area.

“After returning this evening from Los Angeles, where earlier today he had met with police, fire and emergency personnel fighting the historic fires raging in the area and approved a Major Disaster declaration for California, President Biden made the decision to cancel his upcoming trip to Italy to remain focused on directing the full federal response in the days ahead,” White House press secretary Karine Jean-Pierre said in a statement.

Six wind-driven fires blazing across Los Angeles County remain mostly uncontained, with authorities issuing evacuation orders late Wednesday related to a brushfire in the Hollywood Hills near Runyon Canyon.

“Just complete and utter devastation, and I’ve been to a lot of these fires, a lot, going back to Paradise. This approximates Paradise,” Newsom, a Democrat, said.

Biden was scheduled to travel to Rome on Thursday, where the White House said earlier in the day that he’d meet with Pope Francis, Italian Prime Minister Giorgia Meloni, and Italian President Sergio Mattarella.

It’s not the first time domestic issues have forced Biden to upend foreign travel. In October, Biden postponed a scheduled trip to Germany and Angola as Hurricane Milton made landfall. Earlier this week, the White House canceled a scheduled event in Thermal, California, as the wildfires began to spread across the region.

This is a developing story and will be updated.

This post appeared first on cnn.com

Rescue crews found the body of a British hiker buried in the snow of the Italian Alps and were continuing to search for his friend, who had also been missing since January 1, Italy’s rescue services said Wednesday.

Italy’s Alpine rescue service said it only received an alert about the men on January 6, five days after the men set out in the Adamello range near Trento, after they failed to make a scheduled flight home and relatives contacted authorities.

After the first two days of searches were hampered by snowfall, fog and avalanche warnings, rescue crews managed to get a helicopter in the air Wednesday and ground crews reached the pair’s last recorded location.

Guided by the hikers’ phone recordings, crews found the men’s backpacks and equipment, as well as the body of one of the hikers buried in the snow, the rescuers said in a statement.

British media quoted relatives and partners of the two men, Aziz Ziriat, 36, and Sam Harris, 35, as saying they were experienced hikers who had planned a New Year’s Day excursion, hiking from mountain hut to mountain hut.

“It wasn’t surprising that they had no signal as they like going off the grid,” said a university friend of Ziriat, Joe Stone.

A helicopter attempted a flyover on Tuesday, but fog and poor visibility forced it to return before reaching the affected valley and the search was suspended, the rescue crews said.

Additionally, ground crews of the fire rescue service were unable to work due to high risks of avalanches.

The Adamello range straddles Italy’s Lombardy and Trentino-Alto Adige regions and includes the highest peak, Mt. Adamello, at 3,539 meters (11,611 feet.)

This post appeared first on cnn.com

OpenAI co-founder and CEO Sam Altman denied allegations made by his sister in a lawsuit filed Monday, which claimed he sexually abused her for almost a decade.

The lawsuit, filed in federal court in Missouri, accuses him of sexual assault and sexual battery spanning from 1997 to 2006.

His sister, Ann Altman, alleged the sexual abuse began when she was three years old and her brother was 12 at their family home in suburban St. Louis, Missouri, according to the suit.

The abuse included “numerous acts of rape, sexual assault, sexual abuse, molestation, sodomy, and battery,” according to the lawsuit.

She also alleged the last instances of abuse occurred when she was a minor and her brother was an adult.

Altman, in a joint statement with his mother and brothers, said the claims were false and that his sister had struggled with mental health issues and “refuses conventional treatment.”

“All of these claims are utterly untrue. The situation causes immense pain to our entire family,” the statement, posted on X Tuesday, said.

Sam Altman said “Annie” continued to demand money from the family despite financial support.

“Our family loves Annie and is very concerned about her well-being,” the statement said. “Annie receives monthly financial support, which we expect to continue for the rest of her life. Despite this, Annie continues to demand more money from us.”

In response to the Altman family statement, Ann Altman’s lawyer Ryan Mahoney said that “It is not uncommon for parents and other family members to deny (sexual abuse perpetrated by a sibling). In this case, they are focusing on the wrong sibling.”

Mahoney told the Wall Street Journal “there is no evidence that her own mental health has contributed to her allegations.”

Ann Altman, who was 30 when the lawsuit was filed, claimed she has experienced PTSD and extreme emotional distress, mental anguish and depression and has incurred medical bills as a result, according to the lawsuit. She is seeking at least $75,000 in damages.

Ann Altman had previously alleged abuse on her X account beginning in 2021.

The lawsuit says the claims were brought under a Missouri law allowing child sexual abuse victims to file lawsuits up until their 31st birthday. Ann Altman’s X profile indicates she turned 31 on Wednesday, two days after the lawsuit was filed.

Sam Altman is AI’s biggest star — a 39-year-old venture capitalist and the CEO of OpenAI, which kicked off the artificial intelligence wave with its ChatGPT bot. The Microsoft-backed OpenAI had a $157 billion valuation as of October.

OpenAI did not immediately respond to request for comment.

This post appeared first on cnn.com

D-Wave Quantum CEO Alan Baratz said Nvidia’s Jensen Huang is “dead wrong” about quantum computing after comments from the head of the chip giant spooked Wall Street on Wednesday.

Huang was asked on Tuesday about Nvidia’s strategy for quantum computing. He said Nvidia could make conventional chips that are needed alongside quantum computing chips, but that those computers would need 1 million times the number of quantum processing units, called qubits, than they currently have.

Getting “very useful quantum computers” to market could take 15 to 30 years, Huang told analysts.

Huang’s remarks sent stocks in the nascent industry slumping, with D-Wave plunging 36% on Wednesday.

“The reason he’s wrong is that we at D-Wave are commercial today,” Baratz told CNBC’s Deidre Bosa on “The Exchange.” Baratz said companies including Mastercard and Japan’s NTT Docomo “are using our quantum computers today in production to benefit their business operations.”

“Not 30 years from now, not 20 years from now, not 15 years from now,” Baratz said. “But right now today.”

D-Wave’s revenue is still minimal. Sales in the latest quarter fell 27% to $1.9 million from $2.6 million a year earlier.

Quantum computing promises to solve problems that are difficult for current processors, such as decoding encryption, generating random numbers and large-scale simulations. Technologists have been working on it for decades, and companies including Nvidia, Microsoft and IBM are pursuing it today, alongside researchers at startups and universities.

D-Wave was among a number of companies that enjoyed a revival of interest from investors in December, when Google announced a breakthrough in its own research. Google said that it had completed a 100 qubit chip, the second of six steps in its strategy to build a quantum system with 1 million qubits.

D-Wave shares soared 178% in December after popping 185% the month prior. Quantum company Rigetti Computing, which plummeted 45% on Wednesday, quintupled in value last month. IonQ dropped 39% on Wednesday. The stock rose 14% in December following a 143% rally in November.

Baratz acknowledged that one approach to quantum computing, called gate-based, may be decades away. But he said D-Wave uses an annealing approach, which can be deployed now.

While Huang’s “comments may not be totally off-base for gate model quantum computers, well, they are 100% off base for annealing quantum computers,” Baratz said.

Nvidia declined to comment.

Even after Wednesday’s slide, D-Wave shares are up about 600% in the last year, giving the company a market cap of $1.6 billion.

Quantum computing has also been boosted by investor interest in artificial intelligence, the technology that’s led to surging demand for Nvidia’s graphics processing units, which use conventional transistors instead of Qubits. Nvidia’s market cap has increased by 168% in the past year to $3.4 trillion.

Baratz said D-Wave systems can solve problems beyond the capabilities of the fastest Nvidia-equipped systems.

“l’ll be happy to meet with Jensen any time, any place, to help fill in these gaps for him,” Baratz said.

This post appeared first on NBC NEWS

D-Wave Quantum CEO Alan Baratz said Nvidia’s Jensen Huang is “dead wrong” about quantum computing after comments from the head of the chip giant spooked Wall Street on Wednesday.

Huang was asked on Tuesday about Nvidia’s strategy for quantum computing. He said Nvidia could make conventional chips that are needed alongside quantum computing chips, but that those computers would need 1 million times the number of quantum processing units, called qubits, than they currently have.

Getting “very useful quantum computers” to market could take 15 to 30 years, Huang told analysts.

Huang’s remarks sent stocks in the nascent industry slumping, with D-Wave plunging 36% on Wednesday.

“The reason he’s wrong is that we at D-Wave are commercial today,” Baratz told CNBC’s Deidre Bosa on “The Exchange.” Baratz said companies including Mastercard and Japan’s NTT Docomo “are using our quantum computers today in production to benefit their business operations.”

“Not 30 years from now, not 20 years from now, not 15 years from now,” Baratz said. “But right now today.”

D-Wave’s revenue is still minimal. Sales in the latest quarter fell 27% to $1.9 million from $2.6 million a year earlier.

Quantum computing promises to solve problems that are difficult for current processors, such as decoding encryption, generating random numbers and large-scale simulations. Technologists have been working on it for decades, and companies including Nvidia, Microsoft and IBM are pursuing it today, alongside researchers at startups and universities.

D-Wave was among a number of companies that enjoyed a revival of interest from investors in December, when Google announced a breakthrough in its own research. Google said that it had completed a 100 qubit chip, the second of six steps in its strategy to build a quantum system with 1 million qubits.

D-Wave shares soared 178% in December after popping 185% the month prior. Quantum company Rigetti Computing, which plummeted 45% on Wednesday, quintupled in value last month. IonQ dropped 39% on Wednesday. The stock rose 14% in December following a 143% rally in November.

Baratz acknowledged that one approach to quantum computing, called gate-based, may be decades away. But he said D-Wave uses an annealing approach, which can be deployed now.

While Huang’s “comments may not be totally off-base for gate model quantum computers, well, they are 100% off base for annealing quantum computers,” Baratz said.

Nvidia declined to comment.

Even after Wednesday’s slide, D-Wave shares are up about 600% in the last year, giving the company a market cap of $1.6 billion.

Quantum computing has also been boosted by investor interest in artificial intelligence, the technology that’s led to surging demand for Nvidia’s graphics processing units, which use conventional transistors instead of Qubits. Nvidia’s market cap has increased by 168% in the past year to $3.4 trillion.

Baratz said D-Wave systems can solve problems beyond the capabilities of the fastest Nvidia-equipped systems.

“l’ll be happy to meet with Jensen any time, any place, to help fill in these gaps for him,” Baratz said.

This post appeared first on NBC NEWS

A potentially crippling strike up and down America’s East and Gulf Coasts has been avoided – at least for now – after longshoremen and the shipping and port companies reached a tentative deal on a new contract Wednesday.

The United States Maritime Alliance, the group representing ship lines and port and terminal operators, which uses the acronym USMX, and the International Longshoremen’s Association (ILA), a union which represents 50,000 members who fill 25,000 jobs spread between three dozen locations at 14 port authorities from Maine to Texas, jointly announced that they agreed on a six year deal Wednesday. The deal is not complete until it is ratified by the union’s membership.

Without a deal, the port workers were set to go on strike on the morning of January 16.

“We are pleased to announce that ILA and USMX have reached a tentative agreement,” the two sides said in a joint statement. “This agreement protects current ILA jobs and establishes a framework for implementing technologies that will create more jobs while modernizing East and Gulf coast ports – making them safer and more efficient, and creating the capacity they need to keep our supply chains strong.”

“This is a win-win agreement that creates ILA jobs, supports American consumers and businesses, and keeps the American economy the key hub of the global marketplace, the two sides added.”

The ILA and USMX reached a deal in October on wages, which increased hourly pay by 10% in the first year and 62% over the six-year tentative deal. That ended a three-day strike. Workers returned to work and negotiators were sent back to the table to work out the rest of the contract. Negotiators met on Tuesday for the first time since mid-November.

Wednesday’s deal is agreement on all other items including automation, which was a key issue for the union who believed jobs would be lost.

The sides did not publicly disclose the details of the agreement. But a source familiar with the negotiations said that as the final details of the contract were being worked out this week, there was a compromise reached on technology at the ports, Automation was the key sticking point for the union over concerns they would lose jobs.

Fully automated technology is still out of the contract, but it does allow for semi-automation. USMX can implement new technology like cranes that can perform some tasks without human involvement. However, the contract gives the ILA guaranteed jobs directly associated with any new technology, the source said.

Management had argued ports need to introduce technology to improve productivity – not to eliminate union jobs. But the union said it was not convinced its members would go unhurt by new technology.

President Joe Biden had refused calls by many of the nation’s business groups to intervene and order the ILA members back to work during the October strike.

It’s not clear that President-elect Donald Trump would have taken the side of USMX and order the ILA back to work if a new strike started and spilled over into his tenure. After meeting with ILA President Harold Daggett in December, Trump came out firmly in favor of the ILA position on the issue of automation at the ports, writing on his Truth Social platform that the foreign-owned ship lines that dominate the USMX “have made a fortune in the US by giving them access to our markets…. I’d rather these foreign companies spend it on the great men and women on our docks, than machinery, which is expensive, and which will constantly have to be replaced.”

This story has been updated with additional context.

This post appeared first on cnn.com

A potentially crippling strike up and down America’s East and Gulf Coasts has been avoided – at least for now – after longshoremen and the shipping and port companies reached a tentative deal on a new contract Wednesday.

The United States Maritime Alliance, the group representing ship lines and port and terminal operators, which uses the acronym USMX, and the International Longshoremen’s Association (ILA), a union which represents 50,000 members who fill 25,000 jobs spread between three dozen locations at 14 port authorities from Maine to Texas, jointly announced that they agreed on a six year deal Wednesday. The deal is not complete until it is ratified by the union’s membership.

Without a deal, the port workers were set to go on strike on the morning of January 16.

“We are pleased to announce that ILA and USMX have reached a tentative agreement,” the two sides said in a joint statement. “This agreement protects current ILA jobs and establishes a framework for implementing technologies that will create more jobs while modernizing East and Gulf coast ports – making them safer and more efficient, and creating the capacity they need to keep our supply chains strong.”

“This is a win-win agreement that creates ILA jobs, supports American consumers and businesses, and keeps the American economy the key hub of the global marketplace, the two sides added.”

The ILA and USMX reached a deal in October on wages, which increased hourly pay by 10% in the first year and 62% over the six-year tentative deal. That ended a three-day strike. Workers returned to work and negotiators were sent back to the table to work out the rest of the contract. Negotiators met on Tuesday for the first time since mid-November.

Wednesday’s deal is agreement on all other items including automation, which was a key issue for the union who believed jobs would be lost.

The sides did not publicly disclose the details of the agreement. But a source familiar with the negotiations said that as the final details of the contract were being worked out this week, there was a compromise reached on technology at the ports, Automation was the key sticking point for the union over concerns they would lose jobs.

Fully automated technology is still out of the contract, but it does allow for semi-automation. USMX can implement new technology like cranes that can perform some tasks without human involvement. However, the contract gives the ILA guaranteed jobs directly associated with any new technology, the source said.

Management had argued ports need to introduce technology to improve productivity – not to eliminate union jobs. But the union said it was not convinced its members would go unhurt by new technology.

President Joe Biden had refused calls by many of the nation’s business groups to intervene and order the ILA members back to work during the October strike.

It’s not clear that President-elect Donald Trump would have taken the side of USMX and order the ILA back to work if a new strike started and spilled over into his tenure. After meeting with ILA President Harold Daggett in December, Trump came out firmly in favor of the ILA position on the issue of automation at the ports, writing on his Truth Social platform that the foreign-owned ship lines that dominate the USMX “have made a fortune in the US by giving them access to our markets…. I’d rather these foreign companies spend it on the great men and women on our docks, than machinery, which is expensive, and which will constantly have to be replaced.”

This story has been updated with additional context.

This post appeared first on cnn.com

Supreme Court Justice Samuel Alito said he spoke with President-elect Donald Trump by phone this week in support of a former law clerk who is seeking a job in the incoming administration – but the justice said he did not discuss Trump’s pending effort to delay his sentencing.

“William Levi, one of my former law clerks, asked me to take a call from President-elect Trump regarding his qualifications to serve in a government position,” Alito said in a statement issued Wednesday. “I agreed to discuss this matter with President-elect Trump, and he called me yesterday afternoon.”

The call, first reported by ABC News, came one day before Trump filed an emergency appeal seeking to delay his Friday sentencing in his New York hush money case.

It’s not unusual for justices to make job recommendations on behalf of former clerks, who often remain close with the justice for whom they worked. But it is remarkable for justices to speak with an incoming president, especially in advance of a major court filing regarding the first-ever criminal sentencing of a former president.

The call may give the conservative court’s critics another reason to question its independence from politics and Trump in particular. The incoming president named three justices during his first term, and the court has handed down several high-profile opinions in which the six conservatives and three liberals have lined up on opposite sides.

Alito, a member of the court’s conservative wing, has faced repeated calls for recusal from ethics experts and Democrats on Capitol Hill. Most recently, that criticism was focused around two controversial flags that were raised over his properties in Virginia and New Jersey.

In his statement, Alito said he spoke with Trump on Tuesday – and said he did not discuss the case with Trump. The president-elect filed his appeal Wednesday morning.

“We did not discuss the emergency application he filed today, and indeed, I was not even aware at the time of our conversation that such an application would be filed,” Alito said. “We also did not discuss any other matter that is pending or might in the future come before the Supreme Court or any past Supreme Court decisions involving the President-elect.”

The Trump transition did not immediately respond to a request for comment.

Levi clerked for Alito during the 2011 term and has worked in all three branches of the federal government, including in a number of high-profile positions. He served as chief of staff to Attorney General William Barr during the first Trump administration and also worked as chief counsel to Sen. Mike Lee, a Utah Republican.

Trump will face an uphill fight getting the Supreme Court to pause his sentencing because his case is still pending in New York and the nation’s top court is reluctant to take up emergency appeals in that situation.

This story has been updated with additional details.

This post appeared first on cnn.com